Vivtex Corporation is a biotechnology company focused on enabling oral delivery of complex therapeutics, particularly peptide and protein biologics. It develops drug‑delivery and formulation technologies aimed at overcoming gastrointestinal barriers and improving bioavailability.
The company combines gastrointestinal screening and formulation capabilities with proprietary delivery systems and data‑driven optimization to evaluate absorption, stability, and dosage form performance. Vivtex collaborates with biopharmaceutical partners through licensing and R&D programs to advance preclinical development and translation of oral formulations for biologic medicines.
None yet. When a new project in the record names Vivtex as owner, partner or investor, it shows here.
The partnership aims to develop oral biologics for obesity and diabetes, leveraging Vivtex's technology for better bioavailability and Novo Nordisk's expertise in global development and commercialization.
